21
Feb
22
Feb

Dublin

Presented by

IPHA IPHA
BPCI BPCI
NIBRT NIBRT

Speakers

Graham Symcox

Managing Director, PharmaCentaur AG
An overview of the future opportunities and challenges in biopharma manufacturing
Graham has over 25 years of experience providing management consultancy to the global bio and pharmaceutical ..

Matt Moran

Director, BioPharmaChem Ireland
Mauris blandit, erat at scelerisque fringilla, eros neque hendrerit lectus, eget dignissim purus orci id ex. Etiam nec sapien dignissim, iaculis mi et, facilisis est ..

Nigel Darby

Advisor, GE Healthcare Life Sciences
The vendor perspective: The manufacturing facility of the future
Nigel Darby joined GE Healthcare Life Sciences in 2003 and has worked in a variety of executive positions ..

Aine Hanly

PhD, Vice President Drug Substance Technologies and Site Head, Cambridge, Massachusetts, Amgen
Case study on single use manufacturing
Aine Hanly is Vice President, Drug Substance Technologies and Site Head for the Amgen Massachusetts Site in Cambridge (AMA). ..

Dr Humphrey Moynihan

Research Advisor, Eli Lilly
Case study on continuous manufacturing
Humphrey Moynihan received a Ph.D. in Synthetic Organic Chemistry in 1984 from University College Cork ..

Brendan Hughes

Vice President of Manufacturing Sciences and Technology, BMS
Biomanufacturing at BMS: enabling the immuno-oncology revolution
Brendan is Vice President for Manufacturing Sciences and Technology for Biologics for BMS, based in Massachusetts in the US ..

Prof Kieran Hodnett

Scientific Director and Principal Investigator SSPC, University Limerick
The research perspective: New frontiers in pharmaceutical synthesis
Professor Kieran Hodnett joined the University of Limerick (NIHE) in 1984 and has been Professor of Physical Chemistry since 1996. ..

Prof Gavin Davey

Head of School of Biochemistry and Immunology, Trinity College Dublin
The research perspective: Advanced biopharmaceutical technologies
Gavin Davey is based at the Trinity Biomedical Sciences Institute and runs a research group with particular interests in glycobiology, ..

Eddie Reilly

VP, Head of Regulatory CMC & Devices, Sanofi
Industry Panel: Addressing the cost of biopharma manufacturing
Eddie Reilly is a qualified pharmacist, with a post graduate degree in Pharmaceutical Medicine ..

Dr Ian Jones

Founder and CEO, Innopharma Labs
Industry Panel: Addressing the cost of biopharma manufacturing
Dr Jones is the founder and CEO of Innopharma Labs. He has worked for the past 19 years ..

Michael O’Donnell

Vice President Operations and Site Leader, Shanbally, Co. Cork, BioMarin International Ltd
Industry Panel: Addressing the cost of biopharma manufacturing
Michael O’Donnell is Vice President, Operations and Site Leader for the BioMarin Manufacturing Site in Cork ..

Dr Lorraine Nolan

Chief Executive, Health Products and Regulatory Authority
The Regulator’s perspective on the future of biopharma manufacturing
Ms Nolan is a chemist having completed her Ph.D. and post-doctoral research at Trinity College Dublin in transdermal drug delivery ..

Prof Orla Hardiman

Professor of Neurology and Academic Director, Trinity Biomedical Sciences Institute
An introduction to TBSI
Orla Hardiman is Professor of Neurology and Academic Director of Trinity Biomedical Sciences Institute, Trinity College Dublin, ..

Mary Dickens

Vice President, The Irish Pharmaceutical Healthcare Association
Opening remarks
Mary Dickens is the Country Chair and General Manager of General Medicine of Sanofi Ireland ..

Dr Sally Cudmore

General Manager, APC Microbiome Institute
Harnessing the Gut Microbiome
Dr Sally Cudmore is the General Manager of the APC Microbiome Institute with over 250+ scientists ..

Prof Frank Barry

Professor of Cellular Therapy at the Regenerative Medicine Institute, National University of Ireland Galway
Cellular Therapies in Regenerative Medicine
Frank Barry is Professor of Cellular Therapy at the Regenerative Medicine Institute (REMEDI), National University of Ireland Galway ..

Joan O’Callaghan

Research Scientist, Regulatory Science Ireland
What do healthcare professional think about biosimilars?-The Irish survey experience
Joan O’Callaghan is based in HPRA and has been in her current role as a Research Scientist ..

Prof Walter Kolch

Director of Systems Biology Ireland (SBI), University College Dublin
Personalising cancer diagnosis and therapy through computational modelling
Prof Walter Kolch is Director of Systems Biology Ireland (SBI) at University College Dublin (Ireland) ..

Prof William Gallagher

Director, UCD Conway Institute
A driver of transitional research in chronic disease
William Gallagher (WG) is Director of the UCD Conway Institute of Biomolecular and Biomedical Research, ..

Prof Seamas Donnelly

Trinity Biomedical Sciences Institute
The future of precision medicine
Professor Seamas Donnelly is Professor of Medicine at Trinity College Dublin. He is an international leader in Translational Medicine ..

Dr Finbarr O’Sullivan

Associate Director, National Institute for Cellular Biotechnology, Dublin City University
Repairing the cornea and cell based therapies
Finbarr O’Sullivan graduated with a PhD in Cell Biology from Dublin City University (DCU) following studies into the differentiation of lung epithelial cells ..

Nuala McCabe

Head of Research, Internal Products, Almac Diagnostics
Advances in personalised medicines – what’s next in the Almac pipelin
Dr Nuala McCabe graduated from Queen’s University Belfast in 1997 with an Honours Degree in Biomedical Science ..

Steven O’Connell

Associate Director and Programme Manager, IndieBio EU
IndieBio: accelerating biopharma
Steven O Connell is the Associate Director and Programme Manager for IndieBio EU ..

Seamus Fives

Chairman, BioPharmaChem Ireland
Opening remarks
Seamus Fives is the Pfizer Ringaskiddy & Little Island API, Site Leader ..

Dr Michael Kopcha

Director, Office of Pharmaceutical Quality, FDA
Aligning policy regulation, innovation and quality in pharmaceuticals
Michael Kopcha, Ph.D., R.Ph., Director, Office of Pharmaceutical Quality (OPQ), is a leader in the development of innovative solutions to resolve scientific ..

Prof Charles Cooney

FT Haslam Prof of Chemical Engineering, MIT
Industry Panel: From lab to bedside in the future - the convergence of manufacturing and care
Charles L. Cooney received his B.S. in chemical engineering from the University of Pennsylvania ..

Dr Mike Thien

SVP Global Technology and Commercialisation, MSD
Industry Panel: From lab to bedside in the future - the convergence of manufacturing and care
Dr. Thien has worked in new product and process development at Merck for over 25 years. After receiving his B.S. in Chemical Engineering from Caltech (1982) ..

Dr Gerard Fox

Senior Director & Head, Calico Collaboration, AbbVie
Industry Panel: From lab to bedside in the future - the convergence of manufacturing and care
Gerard Fox, Ph.D., is Senior Director, Global Discovery at AbbVie, a global pharmaceutical company employing approximately 28,000 people ..

Dr Bernadette Doyle

Vice President, Global Technical & NPI, Global Manufacturing and Supply, GlaxoSmithKline
Industry Panel: From lab to bedside in the future - the convergence of manufacturing and care
Bernadette joined GSK in 1991, after 3 years as a development chemist with Schering-Plough ..

Prof Luke O’Neill

Chair of Biochemistry, Trinity College Dublin
Industry Panel: Limitless? Harnessing the power of the immune system
Luke O’Neill is Professor of Biochemistry, Trinity College Dublin, where he leads an 18 member research team working on the molecular basis to inflammation and inflammatory diseases. ..

Dr Tom Lillie

Vice President and Head of European Clinical Development, MSD
Industry Panel: Limitless? Harnessing the power of the immune system
Tom Lillie is the Vice President and Head of European Clinical Development for Merck, Sharp and Dohme. Dr Lillie completed his undergraduate training at Brasenose College, University of Oxford ..

Dr Anthony J. Coyle

SVP/CSO Centers for Therapeutic Innovation, Pfizer
Industry Panel: Limitless? Harnessing the power of the immune system
Dr Coyle is the founding CSO of the Centers for Therapeutic Innovation (CTI) and is responsible for CTI’s strategy and scientific direction ..

Elcin Ergun

Executive Vice President, Head of New Businesses, Healthcare, Merck
Industry Panel: Limitless? Harnessing the power of the immune system
Elcin Ergun worked in Global, Regional and Local leadership roles in Pharma industry for more than 20 years including Commercial, Finance and Innovation leadership ..

Prof Garret FitzGerald

Director, Institute for Translational Medicine and Therapeutics, University of Pennsylvania
Industry Panel: Translational Science and Precision Medicine
Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Pharmacology ..

Prof Damian O’Connell

Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG
Industry Panel: Translational Science and Precision Medicine
Damian joined Bayer August 2011 to head up the legacy Clinical Pharmacology Group in GDD ..

Dr Craig Tendler

VP Late-Stage Development and Global Medical Affairs for Oncology, Hematology and Supportive Care, Janssen
Industry Panel: Translational Science and Precision Medicine
Dr Tendler is Vice President, Late-Stage Development and Global Medical Affairs for the Oncology Therapeutic Area at Janssen Research & Development, LLC ..

Dr Damian Page

Group International Scientific Director for Personalized Healthcare and Molecular Information, Global Product Development Medical Affairs, Oncology and Hematology, F.Hoffmann-La Roche
Industry Panel: Translational Science and Precision Medicine
Dr Page is a molecular geneticist who completed his Ph.D. at the University of Zurich, Switzerland ..

Prof Patrick Johnston

President and Vice Chancellor, Queens University Belfast
Accelerating scientific discovery to clinical application – dawn of a new era
Professor Patrick Johnston is President and Vice-Chancellor of Queen’s University Belfast ..

Sir Andrew Dillon

Chief Executive, National Institute for Health and Clinical Excellence
How NICE will influence and facilitate pharmaceutical innovation in health services
Andrew Dillon joined the NHS in 1975 and has held a number of senior management positions, including General Manager ..

Dr Leisha Daly

President, IPHA
End note address
Dr Leisha Daly is Country Director of Janssen, the pharmaceutical company of Johnson & Johnson, a position she assumed in 2008 ..

Dr Darrin Morrissey

Director of Programmes, Science Foundation Ireland
Dr Darrin Morrissey was appointed SFI Director of Programmes in September 2014 ..

Johnathon Marshall

Partner, PwC
Johnathon Marshall is a Partner at PwC where he is an active member of the Operations Leadership team ..


Close